News publication
Everything we hold that kinoxistherapeutics.com published.
Every article we hold from kinoxistherapeutics.com.
Australian biotech Kinoxis Therapeutics raised $14.5 million in Series B backing from Uniseed, UniSuper and others to fund Phase 2 trials of KNX100 for dementia-related agitation, including a new Australian study.
Deals recorded from kinoxistherapeutics.com's coverage. A round is listed once, however many of their articles mention it.
| Company | Stage | Announced | Amount | Investors |
|---|---|---|---|---|
| Kinoxis Therapeutics | Series B | 12 Aug 2024 | $14.5m |
Companies named in kinoxistherapeutics.com's articles, most-covered first.
| Company | What it does | Articles |
|---|---|---|
| Boehringer Ingelheim | 1 | |
| Kinoxis Therapeutics | A clinical candidate that aims to provide an alternative to antipsychotics for managing a… | 1 |
Investors named in kinoxistherapeutics.com's articles, most-covered first.
| Investor | What it does | Articles |
|---|---|---|
| Avicella Capital | 1 | |
| Stoic Venture Capital | 1 | |
| Uniseed | Venture fund backing early-stage deep tech and life science companies | 1 |
| UniSuper | 1 | |
| University of Sydney | 1 |